Faster and Easier Treatment
Compared to the standard IV infusion method, Tecentriq SC offers a remarkable reduction in treatment time, approximately 80% faster. The subcutaneous injections can be completed in just four to eight minutes, whereas the previous IV infusion method took approximately 30-60 minutes.
Expanded Treatment Options
Tecentriq has proven to be an effective treatment option for various types of cancer including lung, liver, bladder, and breast cancer. In the European Union alone, over 38,000 individuals received Tecentriq last year, highlighting its growing importance in cancer care.
Advancing Cancer Homecare Initiatives
Roche is actively collaborating with multiple providers throughout Europe to integrate Tecentriq SC into cancer homecare initiatives. This initiative aims to bring the convenience of administering injections outside the hospital setting, either in a community care facility or even at the patient’s home. However, the precise implementation will depend on national regulations and healthcare systems.
In conclusion, Roche’s approval for Tecentriq SC marks a significant advancement in cancer treatment by providing a faster and easier administration method. With its potential inclusion in cancer homecare initiatives, patients can benefit from more convenient access to this revolutionary immunotherapy.
